Shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) have earned an average broker rating score of 1.00 (Strong Buy) from the four brokers that provide coverage for the company, Zacks Investment Research reports. Four equities research analysts have rated the stock with a strong buy rating.
Brokerages have set a one year consensus price objective of $29.63 for the company and are anticipating that the company will post ($0.48) EPS for the current quarter, according to Zacks. Zacks has also given Milestone Pharmaceuticals an industry rank of 51 out of 256 based on the ratings given to related companies.
A number of equities research analysts recently commented on MIST shares. CIBC started coverage on Uber Technologies in a report on Tuesday, June 4th. They issued an “outperform” rating and a $55.00 price objective for the company. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 3,000 ($39.20) price objective on shares of in a report on Monday, June 3rd. Piper Jaffray Companies downgraded Cypress Semiconductor from an “overweight” rating to a “neutral” rating in a report on Monday, June 3rd. Cowen reiterated a “buy” rating on shares of Odonate Therapeutics in a report on Monday, June 3rd. Finally, Oppenheimer assumed coverage on Tilray in a research note on Tuesday, June 4th. They issued a “market perform” rating for the company.
In other Milestone Pharmaceuticals news, major shareholder Rtw Investments, Lp bought 666,667 shares of the firm’s stock in a transaction on Thursday, May 9th. The stock was purchased at an average cost of $15.00 per share, with a total value of $10,000,005.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Holdings A/S Novo bought 333,333 shares of the firm’s stock in a transaction on Monday, May 13th. The stock was acquired at an average cost of $15.00 per share, with a total value of $4,999,995.00. The disclosure for this purchase can be found here.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc, a biopharmaceutical company, develops and commercializes drugs for the treatment of cardiovascular indications. It offers Etripamil that completed Phase 2 clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as for treating Atrial Fibrillation and Angina.
Featured Story: How Do You Make Money With Penny Stocks?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.